NCT03163992View on ClinicalTrials.gov

Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 26, 2017

Primary Completion Date

May 17, 2021

Study Completion Date

May 17, 2021

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Pembrolizumab

Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)

Trial Locations (1)

Unknown

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT03163992 - Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib | Biotech Hunter | Biotech Hunter